[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1983

Lupus ErythematosusA Clinician's Coign of Vantage

Author Affiliations

McKeesport, Pa

Arch Dermatol. 1983;119(11):877-882. doi:10.1001/archderm.1983.01650350005005
Abstract

Lupus erythematosus (LE), an autoimmune disorder that encompasses a broad spectrum of clinical and laboratory manifestations, denies any solitary explanation as to cause and pathogenesis. Search for such ascertainment has spawned a wide range of clinical and laboratory investigations, the most noteworthy of these being the identification of circulating autoantibodies. The development of these antibody-antigen systems is purported to be the consequence of a defective suppressor T-cell regulatory mechanism1-3; whether this represents cause or effect, however, has yet to be clarified.

More important than this consideration, however, has been the application of these serological markers to clinical use. Consequently, the demonstration of antibodies to nuclear and cytoplasmic antigens in a patient's serum samples has been considered to be the sine qua non for diagnosis and classification of systemic LE (SLE). Such developments have been embraced by the physician with much enthusiasm but yet with some consternation. There is concern

First Page Preview View Large
First page PDF preview
First page PDF preview
×